Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor

J Clin Invest. 1993 Dec;92(6):2922-33. doi: 10.1172/JCI116915.

Abstract

The interaction of LDL and LDL subfractions from a patient homozygous for familial defective apoB-100 (FDB) has been studied. His LDL cholesterol ranged from 2.65 to 3.34 g/liter. In cultured fibroblasts, binding, internalization, and degradation of the patient's LDL was diminished, but not completely abolished. The patient's apolipoprotein E concentration was low, and the amount of apolipoprotein E associated with LDL was not elevated over normal. LDL were separated into six subfractions: LDL-1 (1.019-1.031 kg/liter), LDL-2 (1.031-1.034 kg/liter), LDL-3 (1.034-1.037 kg/liter), LDL-4 (1.037-1.040 kg/liter), LDL-5 (1.040-1.044 kg/liter), and LDL-6 (> 1.044 kg/liter). LDL-5 and LDL-6 selectively accumulated in the patient's plasma. Concentrations of LDL-1 to 3 were normal. The LDL receptor-mediated uptake of LDL-1 and LDL-2 could not be distinguished from normal LDL. LDL-3 and LDL-4 displayed reduced uptake; LDL-5 and LDL-6 were completely defective in binding. When apolipoprotein E-containing particles were removed by immunoabsorption before preparing subfractions, LDL-3 and LDL-4, but not LDL-1 and LDL-2, retained some receptor binding activity. We conclude that in FDB, LDL-1 and LDL-2 contain sufficient apolipoprotein E to warrant normal cellular uptake. In LDL-3 and LDL-4, the defective apoB-100 itself displays some receptor binding; LDL-5 and LDL-6 are inable to interact with LDL receptors and accumulate in plasma.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Apolipoprotein B-100
  • Apolipoproteins B / genetics*
  • Base Sequence
  • Child
  • Cholesterol / blood
  • DNA Primers
  • Female
  • Fibroblasts / metabolism
  • Genetic Carrier Screening
  • Homozygote
  • Humans
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / genetics*
  • Hyperlipoproteinemia Type II / metabolism
  • Lipoproteins / blood
  • Lipoproteins, LDL / genetics*
  • Lipoproteins, LDL / metabolism*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Pedigree
  • Polymerase Chain Reaction
  • Pravastatin / therapeutic use
  • Receptors, LDL / metabolism*
  • Skin / metabolism
  • Triglycerides / blood

Substances

  • Apolipoprotein B-100
  • Apolipoproteins B
  • DNA Primers
  • Lipoproteins
  • Lipoproteins, LDL
  • Receptors, LDL
  • Triglycerides
  • Cholesterol
  • Pravastatin